While it may take several years to finalize the e-registration rule, FDA plans to start accepting electronic listings on a
voluntary basis. In addition to all the envisioned benefits, a more efficient drug registration system would free FDA resources
to implement the new policy and ensure compliance with the rules. Such possibilities are sure to generate many public comments.
Jill Wechsler is the Washington Editor for Pharmaceutical Executive and writes about federal government policies and programs that affect the pharmaceutical industry. Her monthly Washington Report discusses legislative proposals, FDA initiatives and actions by other government agencies, including Medicare pharmacy benefit proposals, federal
investigations related to pharmaceutical company marketing, debate over DTC advertising, generic drug competition, over-the-counter initiatives, among
other topics. She has written for PE for more than ten years and also covers Washington for other Advanstar publications, including Pharmaceutical Technology, Applied Clinical Trials, BioPharm, Managed Healthcare Executive and Formulary. Prior to that she reported on
government policies and a wide range of topics for business and consumer publications.
Articles by Jill Wechsler